The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer

BACKGROUND: Oncotype DX testing has reduced the use of adjuvant chemotherapy in node‐negative early breast cancer but less is known about its impact in node positive patients. AIM: This study aimed to investigate the impact of Oncotype DX gene assay testing on the decision to offer adjuvant chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Malam, Yogeshkumar, Rabie, Mohamed, Geropantas, Konstantinos, Alexander, Susanna, Pain, Simon, Youssef, Mina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351646/
https://www.ncbi.nlm.nih.gov/pubmed/34664429
http://dx.doi.org/10.1002/cnr2.1546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351646/
https://www.ncbi.nlm.nih.gov/pubmed/34664429
http://dx.doi.org/10.1002/cnr2.1546

Ejemplares similares